Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD
2.090
+0.070 (3.47%)
At close: Mar 18, 2026
Revenue by Segment
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | Jun '18 Jun 30, 2018 | Jun '17 Jun 30, 2017 | Jun '16 Jun 30, 2016 |
|---|
Development of Cell Technology Platform for Commercialization | 17.20M | 5.90M | 7.50M | 10.21M | 7.43M | | | | | |
Development of Cell Technology Platform for Commercialization Growth | 191.39% | -21.32% | -26.54% | 37.36% | -76.88% | | | | | |
| 17.20M | 5.90M | 7.50M | 10.21M | 7.43M | | | | | |
| 191.39% | -21.32% | -26.54% | 37.36% | -76.88% | | | | | |
Source: S&P Global Market Intelligence.